Codman Neuro, a part of DePuy Synthes Companies of Johnson & Johnson, has signed a distribution agreement with Pulsar Vascular to market and promote its minimally invasive device PulseRider in Europe, Middle East and Africa (EMEA).

PulseRider is intended for use in conjunction with embolic coils to treat unruptured wide-neck intracranial aneurysms originating on or near a bifurcation.

The agreement was signed by one of Codman Neuro’s affiliated companies in the European Union (EU), and marks the latest expansion of the company’s neurovascular portfolio.

The self-expanding nitinol implant PulseRider, received initial CE Mark approval in Europe in late 2013.

"There is a significant unmet clinical need in the treatment of unruptured, wide-neck bifurcation aneurysms, and we hope to help fill it with this device."

Codman Neuro’s neurovascular portfolio includes a wide range of products for hemorrhagic and ischemic stroke, cerebral aneurysms and other neurovascular and neurological diseases and conditions.

Codman Neuro worldwide president Laxmin Laxminarain said: "We are excited about this new agreement with Pulsar Vascular and the greater access physicians and their patients in Europe will now have to a potentially lifesaving endovascular procedure.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"There is a significant unmet clinical need in the treatment of unruptured, wide-neck bifurcation aneurysms, and we hope to help fill it with this innovative device."

Cerebral aneurysms claims around 500,000 lives a year worldwide, with half the victims younger than 50 years, according to the Brain Aneurysm Foundation.

Paracelsus Medical University Salzburg professor Monika Killer-Oberpfalzer said: "Repairing wide-neck intracranial aneurysms is a challenging endovascular procedure and treatment options are extremely limited.

"We welcome technology specifically designed to enhance our ability to treat these complex aneurysms more easily with less risk in the hope that more lives can be saved."

In the US, PulseRider is limited to investigational use only and the device has not been approved for distribution by the US Food and Drug Administration (FDA).